Bacillus coagulans 198 and L-glutamine in combination attenuated intestinal mucositis in a 5-FU-induced BALB/c mouse model via modulation of gut microbial community structure and diversity
Journal
Journal of Food and Drug Analysis
Journal Volume
33
Journal Issue
1
Start Page
61
End Page
74
ISSN
2224-6614
Date Issued
2025-03-27
Author(s)
Chen, Wei-Jen
Shen, Siou-Ru
Hsu, Wei-Hsuan
Lee, Bao-Hong
Wei, Yu-Shan
Chu, Hui-Fang
Tseng, Ming-Chung
Abstract
5-Fluorouracil (5-FU) disrupts intestinal cells and causes dysbiosis in the gut microbiota. This study explores the potential of Bacillus coagulans-198 (BC198) to mitigate gut microbiota imbalance and mucositis caused by 5-fluorouracil. L-glutamine is used to alleviate mucositis, and this study found that BC198 exhibits protective effects on the gut, including maintaining a healthy microbiota and reducing intestinal inflammation, regardless of whether L-glutamine is used in combination. Therefore, it can help reduce the deterioration of the gut environment caused by 5-fluorouracil. BC198 can be provided to cancer patients to prevent severe side effects, thereby improving their treatment outcomes and nutritional status.
Subjects
5-Fluorouracil (5-FU)
Bacillus coagulans-198 (BC198)
Intestinal inflammation
Microbiota
Mucositis
SDGs
Publisher
The Journal of Food and Drug Analysis (JFDA), Food and Drug Administration, Taiwan (TFDA)
Type
journal article